TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Vitamin D on Angiogenic Factors in Women With Polycystic Ovary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women with PCOS who have vitamin D deficiency (serum 25-hydroxyvitamin D\<20 ng/mL)~Exclusion Criteria:~* Pregnant, postpartum, breast feeding~* Taking Metformin, vitamin D, or any hormonal therapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- Vitamin D3 (Type: ACTIVE_COMPARATOR): Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Women in the placebo group received once capsule of placebo once weekly for eight weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* written consent form~* age\> 25 years~* skinfold thickness \> 0,7 cm BP\> 130/85 mm Hg or a patient on antihypertensive medications fasting blood glucose \> 6.1 mmole/L, or 2-hour postprandial glucose level \> 11.1 mmole/L / or a patient with type 2 diabetes blood cholesterol \> 5.6 mmole/L possibility of treatment \> 6 months follow-up \> 1 year~Exclusion Criteria:~* complete immobilization of a patient (paresis /paralysis)~* patients with severe concomitant diseases of the kidneys and (or) of the liver~* early post-operative condition~* mental illness~* pregnancy~* persons who are in prison~* persons who are in military Armed Forces

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 74 Years
- Healthy Volunteers: t

Study Arms:
- Conventional Patient group (Type: ACTIVE_COMPARATOR): Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin
- Analimentary detoxication Weight loss (Type: EXPERIMENTAL): Vegetables and salt diet
- Healthy people (Type: NO_INTERVENTION): 64 healthy people

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of LBR-101 In Chronic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged 18 to 65 years of age.~* A signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study including any known and potential risks and available alternative treatments.~* Chronic migraine meeting the diagnostic criteria listed in the International Classification of Headache Disorders (ICHD-III beta version, 2013)~* Body Mass Index (BMI) of 17.5 to 37.5 kg/m2, and a total body weight between 50 kg and 120 kg inclusive.~* Demonstrated compliance with the electronic headache diary during the run-in period headache data on a minimum of 22/28 days (80% diary compliance)~Exclusion Criteria:~* Onset of chronic migraine after the age of 50 years.~* Subject has received onabotulinum toxin A for migraine or for any medical or cosmetic reasons requiring injections in the head, face, or neck during the 6 months prior to study entry.~* Subject is using medications containing opioids (including codeine) or barbiturates (including Fiorinal®, Fioricet®, or any other combination containing butalbital) on more than 4 days per month for the treatment of migraine or for any other reason.~* Failed \> 2 medication categories or \> 3 preventive medications (within two medication categories) due to lack of efficacy for prophylactic treatment of episodic or chronic migraine after an adequate therapeutic trial~* Treatment with an investigational drug or device within 30 days of study entry or any prior exposure to a monoclonal antibody targeting the CGRP pathway.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LBR-101 High Dose (Type: EXPERIMENTAL): Subcutaneous High Dose LBR-101 Administered Monthly x 3
- LBR-101 Low Dose (Type: EXPERIMENTAL): Subcutaneous Low Dose LBR-101 Administered Monthly x 3
- Placebo (Type: PLACEBO_COMPARATOR): Subcutaneous Placebo Administered Monthly x 3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Primary Prophylaxis of Esophageal Varices

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Patients of cirrhosis with portal hypertension aged 18 to 75 years who have small esophageal varices with or without red color signs and have not bled previously.~Exclusion Criteria:~* Any contra-indication to beta-blockers~* Any EVL or sclerotherapy within last 3 months~* Child Turcotte Pugh (CTP) score \> 12, refractory ascites, hepatorenal syndrome~* Any past history of surgery for portal hypertension~* Significant cardio or pulmonary co-morbidity~* Any malignancy that affects survival.~* Active alcohol abuse or last intake ≤ 4 weeks to avoid possibility of ongoing alcohol hepatitis.~* Past history of surgery for portal hypertension~* Uncontrolled diabetes~* Peripheral vascular disease~* Refusal to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Carvedilol (Type: EXPERIMENTAL): Tablet Carvedilol 12.5 mg BD or maximum tolerated dose
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets 2 to 4 BD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effectiveness, Compliance of Ibuprofen in a Sustained Release Form in the Treatment of Egyptian Osteoarthritic Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients seeking treatment for osteoarthritis and there are clinical or radiological evidence of the disease,~* Male or female, age ≥ 18~* Designated to treatment with Ibuprofen in a sustained release form (Brufen Retard) according to the best criterion of the physician and if he decides to treat the patient according to labeled indication and dose for 4 weeks.~* Patients who have given their written informed consent to participate in the study~* Patients who are currently taking non steroidal anti inflammatory drugs (NSAIDs), should complete an initial washout phase 10 days depending on the half life of the drug taken~Exclusion Criteria:~* Contraindications as described in company core data sheet (CCDS) and specifically~* Patients with active peptic ulcer~* Patients who have presented reactions of hypersensitivity (asthma , rhinitis or urticaria ) with ibuprofen or other anti-inflammatory non steroids~* Patients with active cardiovascular disease and those taking aspirin/warfarin for prophylaxis for myocardial infarction (MI) or stroke~* Patients with moderate to severe renal diseases~* Patients with moderate to severe hepatic disease~* Patients with Crohn's disease~* Patients included currently in another study~* Women of childbearing potential must not be pregnant~* Any patients the investigators consider ineligible for this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Osteoarthritic patients (Type: None): Patients male or female, age ≥ 18 having clinical or radiological evidence of osteoarthritis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Core Stabilization Exercise in Patients With Subacute Non-Specific Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Onset of back pain within 6 -12 weeks participants had no history of back pain for a period of 6 months prior to the current episode.~* Pain intensity measure by a numerical rating scale (0-10 NRS) and a score of pain at least 3 out of 10.~* Never receive the treatment by core stabilization exercise (CSE) during 3 months before participate in this study.~Exclusion Criteria:~* Pregnancy~* Onset of serious spinal pathology: spinal fracture, spinal tumor or spinal infection.~* Cauda equina syndrome.~* Presented at least 2 out of 3 signs of neurological deficit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Core stabilization exercise (Type: ACTIVE_COMPARATOR): 7-weeks of core stabilization exercise
- conventional treatment (Type: ACTIVE_COMPARATOR): 7-weeks of conventional treatment include therapeutic ultrasound and hot pack

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suspected, presumed or documented infection from any source.~* Initiation of antibiotics.~* Meets Sepsis 3 criteria: The presence of organ dysfunction as identified by a total SOFA score ≥ 2 points above baseline.~* Adult male or female, age between 18 and 85.~* GCS of \>13 with verbal score of 5.~* Signed written informed consent by the patient.~Exclusion Criteria:~* Participation in an interventional investigational trial within 30 days prior to diagnosis of sepsis.~* Significant trauma requiring hospitalization within 30 days prior to diagnosis of sepsis.~* Surgical intervention or hospitalization within 45 days prior to diagnosis of sepsis.~* Pregnancy or breast-feeding female.~* Progressive or poorly-controlled malignancies or \< 6 month after active treatment for cancer (chemotherapy or irradiation).~* Terminally ill patients defined as patients that prior to the current hospitalization are expected to live \< 6 months (as assessed by the physician responsible for the patient).~* Known active acute or chronic viral infections, e.g. Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV) or other chronic infection.~* Known severe chronic respiratory health problems with severe pulmonary hypertension (≥40 mmHg) or respirator dependency.~* Known active upper gastrointestinal (GI) tract ulceration or hepatic dysfunction including but not limited to: biopsy-proven cirrhosis; portal hypertension; episodes of past upper GI bleeding attributed to portal hypertension; or prior episodes of hepatic failure, encephalopathy, or coma.~* Known New York Heart Association (NYHA) class IV heart failure or unstable angina, ventricular arrhythmias, active ischemic heart disease, or myocardial infarction within six months prior to diagnosis of sepsis.~* Known immunocompromised state or medications known to be immunosuppressive.~* Organ allograft or previous history of stem cell transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Allocetra-OTS (Type: EXPERIMENTAL): Standard of Care (SOC) Drug: One dose Allocetra-OTS 140 140x106 /kg
- Allocetra-OTS Two doses (Type: EXPERIMENTAL): Standard of Care (SOC) Drug: Two doses Allocetra-OTS 140 140x106 /kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Outpatients~2. ≥18 yrs old,~3. Prior history of colorectal resection due to colo-rectal cancer, referred for surveillance colonoscopy~Exclusion Criteria:~1. Inpatients~2. Emergency Colonoscopy~3. Comorbidities: Congestive heart failure, history of kidney disease, history of solid organ transplant~4. Pregnant and/or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bisacodyl plus 2-Liter Polyethylene glycol (Type: ACTIVE_COMPARATOR): Patients randomized to the low-volume arm, will be invited to consume 2 sachets of Lovol-esse (Polyethylene glycol) in one liter of water at 8:00 PM the evening before the colonoscopy and 2 sachets in one liter of water 4 hours before their scheduled colonoscopy appointment; furthermore, the patients will be instructed to take three 5-mg tablets of bisacodyl the day before the procedure, at 5:00 PM.
- 4-Liter Polyethylene glycol (Type: ACTIVE_COMPARATOR): Patients assigned to the high-volume arm will be invited to consume 2 envelopes of Selg-esse 1000 (polyethylene glycol) in 2 litres of water and drink the resulting solution in about 2-3 hours starting at 6:00 PM the evening before the colonoscopy; the day of the procedure, starting 5 hours before the procedure, the patients will be invited to complete the preparation with 2 others envelopes of Selg-esse 1000 (polyethylene glycol) dissolved in 2 litres of water.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with established diagnosis of low to moderate adult rheumatoid arthritis, currently on Disease Modifying AntiRheumatic Drugs (DMARDs) therapy for at least six months and not longer than 10 years~Exclusion Criteria:~* All the concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment, or with the safety of the patient~* Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trial~* Patients must not have received any previous biological therapy for rheumatoid arthritis (RA)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab pegol 200 mg (CDP870) (Type: EXPERIMENTAL): Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
- Placebo (Type: PLACEBO_COMPARATOR): Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a live twin living in the same household who is also enrolled in this study.~* Born after a gestation period of ≥32 weeks,~* Discharged from hospital neonatal care stay,~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.~* A male or female between, and including, 6 and 14 weeks of age at the time of the first study vaccination.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Written informed consent obtained from the parent or guardian of the subjects.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).~* Any clinically significant history of chronic gastrointestinal disease.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Acute disease at time of enrolment.~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~* Contact with an immunosuppressed individual.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).~* Chronic administration of immunosuppressants since birth.~* Gastroenteritis within 7 days preceding the first study vaccine administration.~* Documented HIV-positive subject.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 14 Weeks
- Healthy Volunteers: t

Study Arms:
- Rotarix Group (Type: EXPERIMENTAL): All subjects received 2 oral doses of Rotarix vaccine at Day 0 (Visit 1) and Week 7 (Visit 2).~Subjects aged less than 6 months at Visit 3 received one complimentary Rotarix vaccine dose at Week 13 (Visit 3).
- Placebo Group (Type: PLACEBO_COMPARATOR): All subjects received 2 oral doses of placebo at Day 0 (Visit 1) and Week 7 (Visit 2).~Subjects aged less than 6 months at Visit 3 received one complimentary Rotarix vaccine dose at Week 13 (Visit 3).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Music for Pain in Primary Dysmenorrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Legal and cognitive capacity for informed consent.~* Suffering from primary dysmenorrhea (low abdominal pain associated to menses).~* Being able to understand and use the measuring tools and questionnaires.~Exclusion Criteria:~* Previous diagnosis of pelvic pathology.~* Diagnosis of hearing impairment.~* Diagnosis of neurologic or endocrinological disease.~* Psychiatric condition diagnosed.~* Known or reported previous substance abuse.~* Current use of psychiatric drugs.~* Cancer diagnosis~* Diagnosed diabetes mellitus or heart disease.~* Previous advance musical training (defined as any form of music training in addition to that received during normal school classes).~* Irregular menstrual cycles.~* Previous pregnancy.~* Current use or use of any hormonal contraceptive therapy in the last 2 months.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Music group (Type: EXPERIMENTAL): Patients in this arm listened through headphones to a song of 29 minutes and 32 seconds duration. The song was composed entirely by investigator Juan Martin-Saavedra and registered to copyright and authorship regulatory entities from Colombia under the name Occasio adolore (Musical piece No. 5-559-355 and Phonogram No. 12-105-295 of Colombia's Copyright authorship agency). Patients were instructed to avoid using cellphones or other activities during the time of the intervention. Patients receive the intervention in the same room as the Silence group, but for the intervention they were always alone. The room was located in a low transit place with low ambient noise.
- Silence group (Type: ACTIVE_COMPARATOR): Patients on the silence group listened to a 29 minute and 32 second audio file that produced no sounds with headphones on. Patients were instructed to avoid using cellphones or other activities during the time of the intervention. Patients receive the intervention in the same room as the Music group, but for the intervention they were always alone. The room was located in a low transit place with low ambient noise.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete